Research · 10 min read
What a Medication Guide Is, and Who Has to Give You One
It is not a marketing leaflet. It is FDA-approved patient labeling whose content, headings and order are set by federal regulation, and the duty to hand it to you falls on whoever dispenses the drug — including at a distance.
Key takeaways
- A Medication Guide is FDA-approved patient labeling defined by 21 CFR Part 208, not a leaflet a company chose to write.
- It must not be promotional in tone or content, and must not conflict with the approved professional labeling.
- FDA requires one where patient labeling could help prevent serious adverse effects, where risk information could affect a decision to use the drug, or where adherence is crucial.
- The headings and their order are prescribed, and the first one holds the concern FDA decided created the need for the guide.
- The duty to hand it to you falls on the authorized dispenser at the moment of dispensing, on new prescriptions and on refills, with no exception for distance.
- A prescriber may direct that a particular patient not receive one, but the dispenser must still provide it to any patient who asks.
- A compounded preparation has no FDA-approved labeling, so Part 208 produces no Medication Guide for it.
Answer first: a regulated document with a named owner of the duty
A Medication Guide is defined in federal regulation as FDA-approved patient labeling. Its content, its headings and the order of those headings are set by 21 CFR Part 208, and a manufacturer has to get FDA approval of the guide before it may be distributed at all.
Two rules follow from that definition and are worth knowing before reading one. The guide must not be promotional in tone or content. And it must be scientifically accurate and based on, and not in conflict with, the approved professional labeling for the product.
The duty to actually place it in your hands sits with the dispenser. Each authorized dispenser of a product for which a guide is required must, when the product is dispensed to a patient or a patient's agent, provide the guide directly to that person. A mail-order pharmacy is a dispenser like any other.
The part also states that it applies to new prescriptions and refill prescriptions. It is not a one-time document handed over at the start.
Why FDA requires one for some drugs and not others
Part 208 says it applies to prescription drug products that FDA determines pose a serious and significant public health concern requiring distribution of FDA-approved patient information. It applies primarily to products used on an outpatient basis without direct supervision by a health professional.
Read that description against this category and it fits almost exactly. A weekly injection or a daily tablet taken at home, without anyone present, is the case the rule was written around.
The regulation then lists three circumstances, any one of which can trigger the requirement. The product is one for which patient labeling could help prevent serious adverse effects. Or it has serious risks relative to benefits that patients should be aware of, because information about those risks could affect a decision to use or continue the product. Or the product is important to health and adherence to directions is crucial to its effectiveness.
So the existence of a guide is itself a signal. It records a written FDA determination that the information was necessary to safe and effective use, not a manufacturer's decision to be helpful.
The headings are prescribed, and so is their order
This is the part almost nobody knows. The regulation lists the headings a guide must contain, relevant to the product, in a specified order, and it says what belongs under each one.
The first is the heading asking what is the most important information the reader should know. Under it goes a statement describing the particular serious and significant public health concern that created the need for the guide. Then a heading asking what the drug is, which may not name an indication unless it appears in the indications section of the professional labeling. Then a heading covering the circumstances in which the product should not be used, with directions on what to do if one applies. Then one on proper use, then one on what to avoid, then one on possible or reasonably likely side effects.
Two of those headings carry very specific duties. The proper-use heading is where a statement about a missed dose belongs, and the regulation attaches a condition to it. It applies where there are data to support the advice, and where the wrong behavior could cause harm or lack of effect. The side-effects heading requires a verbatim sentence telling readers to call their doctor for medical advice about side effects, and giving FDA's reporting number.
Compare that with the numbered warnings in the professional label, where the regulation sets no ordering rule at all. The document written for a clinician has an unordered list of hazards. The document written for a patient has a prescribed sequence, and it opens with the single thing FDA decided mattered most.
What is in the first slot on these particular guides
All six of the approved labels examined here carry a Medication Guide, and all six fill that first slot the same way. The most important information is the possible thyroid tumor finding, the symptoms to report, and the statement that it is not known whether the drug will cause those tumors in people.
Each then gives the circumstances in which the product should not be used, and each names two rather than one. A personal or family history of medullary thyroid carcinoma, or the endocrine condition abbreviated MEN 2. And a prior serious allergic reaction to the active ingredient or to any of the ingredients in the product, with a pointer to the ingredient list printed at the end of the guide.
The guides then use a plain-language block rather than a question heading for the things to tell a prescriber about beforehand. The list runs to pancreas problems, severe stomach problems including slowed stomach emptying, and a history of diabetic retinopathy. It continues with scheduled surgery or a procedure using anesthesia or deep sedation, pregnancy or plans to become pregnant, and breastfeeding. Each guide is itself FDA-approved, so the wording on the page is the wording FDA approved for that product.
The side-effects section is where the same-day items sit, in ordinary words. Stop using the drug and call a healthcare provider right away for severe stomach-area pain that will not go away. Stop and get medical help right away for symptoms of a serious allergic reaction, which the guides then list. That is the same material the professional label carries, written for the person holding the pen or the bottle.
Who is on the hook for getting it to you
The chain is spelled out. A manufacturer shipping a container of a product for which a guide is required must ensure guides are available for distribution to patients. It can do that by supplying enough of them, or by supplying the means to produce them. A distributor or packer that receives them must pass them on to each dispenser it ships product to.
The container or package label must instruct the dispenser to provide a guide to each patient, and must state how it is provided, in a prominent and conspicuous manner.
Then the operative sentence: each authorized dispenser must, when the product is dispensed to a patient or the patient's agent, provide a Medication Guide directly to that person, unless an exemption applies. An authorized dispenser is defined as someone licensed or otherwise permitted by their jurisdiction to provide drug products on prescription.
None of that is conditional on the pharmacy being down the road. If a licensed pharmacy dispenses an approved product to you by mail, the same duty attaches, and a guide should be in the box or provided in the way the label states.
The two exemptions, and the one that cannot be waived
FDA may exempt or defer any content or format requirement, on its own initiative or in response to a written request. The basis has to be that the requirement is inapplicable, unnecessary, or contrary to patients' best interests. Two requirements are excluded from that power. One is the rule that the guide be scientifically accurate and not conflict with the professional labeling. The other is the rule that it carry the words Medication Guide prominently at the top, and the verbatim statement that FDA has approved it.
The second exemption is about individual patients. A prescriber who determines that receiving a guide is not in a particular patient's best interest, because of significant concerns about its effect, may direct that it not be provided to that patient.
The sentence that follows is the one worth remembering. The dispenser must provide a Medication Guide to any patient who requests information when the product is dispensed, regardless of any such direction. Asking overrides it.
Where a compounded preparation sits in all this
Part 208 is built entirely around approved products. A Medication Guide is defined as FDA-approved patient labeling. FDA determines in writing that patient labeling is necessary. A manufacturer must obtain FDA approval of the guide before distributing it.
A compounded preparation has no FDA-approved labeling, so nothing in this part produces a Medication Guide for it. That is a scope fact about the regulation rather than a safety finding about any pharmacy, and the same point applies to the approved prescribing information more generally.
It does change what a reader can reasonably ask for. With an approved product, there is a document that has to arrive and a defined party who has to hand it over. With a compounded preparation, whatever patient information arrives is the compounder's own, prepared under state pharmacy practice rather than approved by FDA, and there is no federal heading list behind it.
The practical version is a question rather than a conclusion. Ask what patient information comes with the product, who wrote it, and whether anything about it has been reviewed by anyone outside the company selling it.
Two things to check on the one you were given
The first is the revision date. The regulation requires the date of the most recent revision, identified as such, placed immediately after the last section. On these six products the guide's revision date and the version date of the professional labeling it accompanies are not always close together. On one of them, the guide prints a revision date more than a year older than the labeling version it shipped with. That is not an error, because a guide is revised when its own content changes. It does mean the date on the guide answers a narrower question than people assume.
The second is the closing statement. All six of these guides carry the verbatim sentence stating that the guide has been approved by the U.S. Food and Drug Administration, which the regulation requires at the bottom and which FDA cannot waive. A patient-facing leaflet without it is not a Medication Guide, whatever else it may be.
One more line the regulation requires, and every one of these guides carries: medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. That sentence exists so that the guide's own list of uses is not read as the boundary of legitimate prescribing.
Sources
- 21 CFR Part 208 — Medication Guides for Prescription Drug ProductsEvery regulatory statement in this article. Section 208.1 for the scope covering products that pose a serious and significant public health concern, the application primarily to outpatient use without direct supervision by a health professional, the application to new and refill prescriptions, the requirement that FDA determine in writing, and the three triggering circumstances. Section 208.3 for the definitions of authorized dispenser and of Medication Guide as FDA-approved patient labeling. Section 208.20 for the non-promotional requirement, the requirement not to conflict with the professional labeling approved under 201.57, the prominent heading and the verbatim FDA approval statement, the prescribed headings in the specified order, the missed-dose condition, the verbatim side-effect reporting sentence, the verbatim statement that medicines are sometimes prescribed for other purposes, and the revision date placed immediately after the last section. Section 208.24 for the manufacturer, distributor and packer supply chain, the container label instruction, and the dispenser's duty to provide a guide directly to each patient. Section 208.26 for the exemption power and the two requirements excluded from it, and for the prescriber direction together with the sentence requiring provision to any patient who requests information.
- WEGOVY (semaglutide) injection and tablets — full prescribing information, Medication GuideThe thyroid statement in the most-important-information slot; the two do-not-use circumstances including a prior serious allergic reaction to the drug or any of its ingredients with a pointer to the ingredient list; the instruction to read the guide before starting and at each refill; the same-day instructions on severe abdominal pain and serious allergic reaction; the verbatim FDA reporting sentence; the verbatim statement that medicines are sometimes prescribed for other purposes; and the printed revision date.
- ZEPBOUND (tirzepatide) injection — full prescribing information, Patient Medication GuideThe verbatim FDA approval statement and printed revision date; the thyroid statement in the first slot; the two do-not-use circumstances; the list of conditions to tell a healthcare provider about before use, including pancreas problems, slowed stomach emptying, a history of diabetic retinopathy and scheduled surgery or a procedure using anesthesia or deep sedation; the stop-and-call instructions; and the verbatim FDA reporting sentence.
- MOUNJARO (tirzepatide) injection — full prescribing information, Medication GuideThe verbatim FDA approval statement; the thyroid statement in the first slot; the two do-not-use circumstances; and the verbatim FDA reporting sentence.
- OZEMPIC (semaglutide) injection — full prescribing information, Medication GuideThe guide whose printed revision date is more than a year older than the version date of the labeling it accompanies; the instruction to read the guide before starting and at each refill; the two do-not-use circumstances; and the verbatim FDA approval and reporting statements.
- RYBELSUS (semaglutide) tablets and OZEMPIC (semaglutide) tablets — full prescribing information, Medication GuideA single Medication Guide covering two brand names; the instruction to read it before starting and at each refill; the two do-not-use circumstances; and the verbatim FDA approval and reporting statements.
- FOUNDAYO (orforglipron) tablets — full prescribing information, Medication GuideThe verbatim FDA approval statement and issue date; the thyroid statement in the first slot; the two do-not-use circumstances; the conditions to report before starting; and the verbatim FDA reporting sentence.
Frequently asked questions
Is a Medication Guide the same thing as the leaflet in the box?
Not necessarily. A Medication Guide is a specific regulated document — FDA-approved patient labeling, whose content and heading order are set by 21 CFR Part 208. It must carry the words Medication Guide at the top and a verbatim statement of FDA approval. The Instructions for Use, which explains how to handle a particular pen or vial, is a different document, and several of these products carry more than one of those for different presentations. A pharmacy's own printed information sheet is a third thing again.
Does a mail-order or telehealth pharmacy have to give me one?
The regulation places the duty on each authorized dispenser of a product for which a guide is required, at the moment it is dispensed to a patient or the patient's agent. An authorized dispenser is defined as someone licensed or otherwise permitted by their jurisdiction to provide drug products on prescription. Nothing in that turns on the pharmacy's distance from you. The container label is also required to instruct the dispenser to provide the guide and to state how it is provided.
Do I get one again with a refill?
Part 208 states in its scope that it applies to new prescriptions and refill prescriptions. Three of the six guides examined here also open by telling the reader to read the guide before starting and each time they get a refill, adding that there may be new information. That is the reason to look at the revision date rather than assuming this copy matches the last one.
Can a prescriber decide I should not get one?
The regulation allows it in narrow terms. A prescriber who determines that receiving a guide is not in a particular patient's best interest, because of significant concerns about its effect, may direct that it not be provided. The next sentence is the important one. The dispenser must provide a guide to any patient who requests information when the product is dispensed, regardless of any such direction. Asking for it overrides the instruction.
Does a compounded semaglutide or tirzepatide come with a Medication Guide?
No, and the reason is definitional rather than a judgment about any pharmacy. Part 208 defines a Medication Guide as FDA-approved patient labeling, requires FDA to determine in writing that patient labeling is necessary, and requires a manufacturer to obtain FDA approval of the guide before distribution. A compounded preparation has no FDA-approved labeling, so no document in this category exists for it. Whatever patient information arrives with one is the compounder's own.
What is actually in the first section of these guides?
The regulation puts a specific thing there: a statement describing the particular serious and significant public health concern that created the need for the guide. On all six approved labels examined here, that slot holds the possible thyroid tumor finding and the symptoms to report to a healthcare provider. It also holds the statement that it is not known whether the drug will cause those tumors in people. The circumstances in which the product should not be used follow immediately, and each of these guides names two of them rather than one.